These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 7574507)
1. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Roberts WL; Berman JD; Rainey PM Antimicrob Agents Chemother; 1995 Jun; 39(6):1234-9. PubMed ID: 7574507 [TBL] [Abstract][Full Text] [Related]
2. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Sereno D; Cavaleyra M; Zemzoumi K; Maquaire S; Ouaissi A; Lemesre JL Antimicrob Agents Chemother; 1998 Dec; 42(12):3097-102. PubMed ID: 9835497 [TBL] [Abstract][Full Text] [Related]
3. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria. Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages. Cantos G; Barbieri CL; Iacomini M; Gorin PA; Travassos LR Biochem J; 1993 Jan; 289 ( Pt 1)(Pt 1):155-60. PubMed ID: 8424752 [TBL] [Abstract][Full Text] [Related]
5. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Ephros M; Waldman E; Zilberstein D Antimicrob Agents Chemother; 1997 May; 41(5):1064-8. PubMed ID: 9145870 [TBL] [Abstract][Full Text] [Related]
6. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. Walker J; Saravia NG J Parasitol; 2004 Oct; 90(5):1155-62. PubMed ID: 15562618 [TBL] [Abstract][Full Text] [Related]
9. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. Wyllie S; Cunningham ML; Fairlamb AH J Biol Chem; 2004 Sep; 279(38):39925-32. PubMed ID: 15252045 [TBL] [Abstract][Full Text] [Related]
10. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity. Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589 [TBL] [Abstract][Full Text] [Related]
11. In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. da Luz RI; Vermeersch M; Dujardin JC; Cos P; Maes L Antimicrob Agents Chemother; 2009 Dec; 53(12):5197-203. PubMed ID: 19752271 [TBL] [Abstract][Full Text] [Related]
12. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis. Roberts WL; Hariprashad J; Rainey PM; Murray HW Am J Trop Med Hyg; 1996 Oct; 55(4):444-6. PubMed ID: 8916804 [TBL] [Abstract][Full Text] [Related]
13. A protein of the leucine-rich repeats (LRRs) superfamily is implicated in antimony resistance in Leishmania infantum amastigotes. Genest PA; Haimeur A; Légaré D; Sereno D; Roy G; Messier N; Papadopoulou B; Ouellette M Mol Biochem Parasitol; 2008 Mar; 158(1):95-9. PubMed ID: 18164495 [TBL] [Abstract][Full Text] [Related]
14. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy. Carter KC; Hutchison S; Boitelle A; Murray HW; Sundar S; Mullen AB Parasitology; 2005 Dec; 131(Pt 6):747-57. PubMed ID: 16336728 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite. Gomes ML; DeFreitas-Silva G; dos Reis PG; Melo MN; Frézard F; Demicheli C; Idemori YM J Biol Inorg Chem; 2015 Jul; 20(5):771-9. PubMed ID: 25929728 [TBL] [Abstract][Full Text] [Related]
16. In vivo antileishmanial properties of pentavalent antimonial compounds. Neal RA; Matthews PJ Trans R Soc Trop Med Hyg; 1982; 76(2):284. PubMed ID: 6285557 [No Abstract] [Full Text] [Related]
17. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. Berman JD; Lee LS J Parasitol; 1984 Apr; 70(2):220-5. PubMed ID: 6088749 [TBL] [Abstract][Full Text] [Related]
18. Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Kuryshev YA; Wang L; Wible BA; Wan X; Ficker E Mol Pharmacol; 2006 Apr; 69(4):1216-25. PubMed ID: 16418337 [TBL] [Abstract][Full Text] [Related]
19. Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line. Wyllie S; Fairlamb AH Biochem Pharmacol; 2006 Jan; 71(3):257-67. PubMed ID: 16318845 [TBL] [Abstract][Full Text] [Related]
20. Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds. Ravinder ; Bhaskar ; Gangwar S; Goyal N Curr Microbiol; 2012 Dec; 65(6):696-700. PubMed ID: 22945482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]